The fatty acid amide hydrolase inhibitor URB 597: Interactions with anandamide in rhesus monkeys

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 655-666

  Stewart, Jennifer L ^a   McMahon, Lance R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

9 tetrahydrocannabinol; anandamide; cannabinoid; drug discrimination; rhesus monkey; rimonabant; URB 597

Indexed keywords

ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; CARBAMATES; DISCRIMINATION (PSYCHOLOGY); DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; MACACA MULATTA; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; TETRAHYDROCANNABINOL;

EID: 80052220065     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01388.x     Document Type: Article

References (46)

1. Adams IB, Compton DR, Martin BR, (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284: 1209-1217. (Pubitemid 28130853)
2. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158: S1-S254.
3. Castelli MP, Paola Piras A, D'Agostino A, Pibiri F, Perra S, Gessa GL, et al,. (2007). Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2. Eur J Pharmacol 573: 11-19. (Pubitemid 47464211)
4. Childers SR, (2006). Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J 8: E112-E117.
5. Chung T, Martin CS, Cornelius JR, Clark DB, (2008). Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction 103: 787-799. (Pubitemid 351537680)
6. Clapper JR, Mangieri RA, Piomelli D, (2009). The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56: 235-243.
7. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277: 586-594. (Pubitemid 27168965)
8. Cornelius JR, Chung T, Martin C, Wood DS, Clark DB, (2008). Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. Addict Behav 33: 1500-1505.
9. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al,. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376. (Pubitemid 32743923)
10. 1 receptors in the least shrew. Pharmacol Biochem Behav 69: 239-249. (Pubitemid 32566269)
11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
12. 9-tetrahydrocannabinol-tolerant rats. J Neurochem 74: 1627-1635. (Pubitemid 30163985)
13. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al,. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358. (Pubitemid 40411361)
14. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND, (1999). Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288: 478-483. (Pubitemid 29119654)
15. Giuffrida A, Piomelli D, (1998a). Purification and high-resolution analysis of anandamide and other fatty acylethanolamides. In:, Laychock SG, Rubin RP, (eds). Lipid Second Messengers. CRC: Boca Raton, FL, pp. 113-133.
16. Giuffrida A, Piomelli D, (1998b). Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett 422: 373-376. (Pubitemid 28075498)
17. Grotenhermen F, (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42: 327-360. (Pubitemid 36433875)
18. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC, (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
19. 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 156: 369-380. (Pubitemid 32695845)
20. Jhaveri MD, Richardson D, Chapman V, (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 152: 624-632. (Pubitemid 350034979)
21. Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, et al,. (2011). Fatty acid amide hydrolase (FAAH) inhibition reduces L-DOPA-induced hyperactivity in the MPTP-lesioned non-human primate model of Parkinson's disease. J Pharmacol Exp Ther 336: 423-430.
22. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al,. (2008). Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64: 930-937.
23. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al,. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81. (Pubitemid 36098263)
24. Kenakin T, (1997). Pharmacologic Analysis of Drug-receptor Interaction. Lippincott-Raven: Philadelphia, PA.
25. 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 126: 125-131. (Pubitemid 26246762)
26. 1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 160: 615-626.
27. 9-tetrahydrocannabinol. Psychopharmacology 203: 219-228.
28. 9-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162: 1060-1073.
29. McMahon LR, Sell SL, France CP, (2004). Cocaine and other indirect-acting monoamine agonists differentially attenuate a naltrexone discriminative stimulus in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 308: 111-119. (Pubitemid 38090708)
30. 2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299-308.
31. Naidu PS, Booker L, Cravatt BF, Lichtman AH, (2009). Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 329: 48-56.
32. National Research Council (2003). Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. National Academies Press: Washington, DC.
33. Panlilio LV, Justinova Z, Goldberg SR, (2010). Animal models of cannabinoid reward. Br J Pharmacol 160: 499-510.
34. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al,. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
35. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, et al,. (2009). Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11: 342-352.
36. Sell SL, McMahon LR, Koek W, France CP, (2005). Monoaminergic drugs and directly observable signs of LAAM withdrawal in rhesus monkeys. Behav Pharmacol 16: 53-58. (Pubitemid 40354366)
37. Sharir H, Abood ME, (2010). Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301-313.
38. Solinas M, Justinova Z, Goldberg SR, Tanda G, (2006). Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98: 408-419. (Pubitemid 44133146)
39. 9- tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321: 370-380. (Pubitemid 46456957)
40. 9- tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334: 347-356.
41. Tallarida RJ, (2000). Drug Synergism and Dose-effect Data Analysis. Chapman and Hall/CRC: Boca Raton, FL, pp. 44-50.
42. Tallarida RJ, (2006). An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319: 1-7. (Pubitemid 44455105)
43. Wiley J, Balster R, Martin B, (1995). Discriminative stimulus effects of anandamide in rats. Eur J Pharmacol 276: 49-54.
44. Wiley JL, Golden KM, Ryan WJ, Balster RL, Razdan RK, Martin BR, (1997). Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys. Pharmacol Biochem Behav 58: 1139-1143. (Pubitemid 28108227)
45. Wiley JL, Razdan RK, Martin BR, (2006). Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice. Life Sci 80: 24-35. (Pubitemid 44809295)
46. Willoughby KA, Moore SF, Martin BR, Ellis EF, (1997). The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282: 243-247. (Pubitemid 27425547)